Exevir at ECCMID 2024
Our Chief Scientific Officer Viki Bockstal is presenting a poster at ECSMID Global 2024 (formerly known as ECCMID) from 27-30 April in vibrant Barcelona, the Mediterranean’s #lifesciences hub!
Bio-Europe – November 6-8, 2023 – Munich, Germany
Our CEO Torsten Mummenbrauer is attending #BIOEurope in Munich, November 6-8!
Bio International Convention – June 5-8, 2023 – Boston, USA
Our CEO and COO are attending this partnering event in person to explore opportunities to collaborate in delivering new medicines to prevent and treat infectious diseases in patients.
Antibody Engineering & Therapeutics Europe 2023 – June 6-8, 2023 – Amsterdam, The Netherlands
Our Head of Preclinical Development is attending this event in person to meet the antibody community.
Bio€quity Europe— May 12-14, 2023 – Dublin, Ireland
Excited to be a part of the Presenting Company Class of 2023 at BioEquity: Europe 2023!
Bio Partnering at JPM — January 9-12, 2023 – San Francisco, CA
ExeVir is a clinical-stage company developing novel antibody therapies that help patients ward off infectious diseases. Our focus is on protecting populations unable to benefit from vaccines, such as immunocompromised individuals. The versatile VHH platform enables both prevention and treatment of bacterial and viral threats.